REGISTER HERE.

The annual Master's of Pediatric Dermatology Symposium (MOPD) is a one and half-day session was initially developed to promote and advance education surrounding skin diseases & disorders in pediatric age groups, and to foster an exchange of information between physicians and health professionals interested in the field of pediatric dermatology.

This year's MOPD Symposium will allow attendees to learn the latest treatment approaches, protocols, procedures, and tools needed to support children with dermatologic conditions, and ultimately provide better, more personalized care for this specific population of younger patients.

TARGET AUDIENCE

The Masters of Pediatric Dermatology symposium is designed to meet the needs of pediatric dermatologists, pediatricians, family practitioners, dermatologists, nurses/nurse practitioners and residents in these programs.

EDUCATIONAL OBJECTIVES

Upon completion of the educational activity, participants should be able to:

• Identify effective patient/caretaker communication and education strategies to improve patient adherence to prescribed therapy for chronic dermatologic conditions.
• Choose appropriate therapy for psoriasis in children and adolescents based on disease severity and available evidence.
• List recent advances in pediatric atopic dermatitis knowledge and treatment.
• Examine the efficacy and safety of current non-pharmacological and pharmacological treatments for AD patients across the age spectrum.
• Select appropriate therapies for treatment of acne in children from newborns to preteens.
• Identify therapeutic advances for pigmented lesions and vitiligo in the pediatric population.
• Discuss recent therapeutic updates for hyperhidrosis, impetigo, acne, and molluscum in pediatric population.
• Select appropriate therapy for childhood hair loss disorders such as alopecia areata based on diagnosis and available evidence behind current and emerging treatments.
• Discuss recent research into the treatment of cutaneous warts and molluscum contagiosum.
• Choose appropriate therapy for management and treatment of epidermolysis bullosa.

ACCREDITATION

AKH Inc., Advancing Knowledge in Healthcare designates this enduring activity for a maximum of 9.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For more information please visit the official event page.